Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06706752 · ClinicalTrials.gov registry record · NA

A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy

A NA study of Cancer, sponsored by Sutter Health.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06706752 is a NA study of Cancer that is actively recruiting participants, run by Sutter Health. The registered enrollment target is 30 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06706752, a NA study of Cancer, is actively recruiting participants, sponsored by Sutter Health.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to assess whether Shengbai Oral Formula is a viable option for treatment of fatigue, pain, and neutropenia in patients undergoing their third cycle of chemotherapy.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Shengbai Oral Formula
  • OTHER Inactive Placebo

Study Locations (1)

California

  • Sutter Health - Oakland

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-01-24
Est. Completion 2025-12
Phase NA

Sponsor

Sutter Health

9 total trials

What the Registry Record Tells You About NCT06706752

The ClinicalTrials.gov registry entry for NCT06706752 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Sutter Health, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Shengbai Oral Formula is the first listed.

NCT06706752 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06706752 about?

NCT06706752 is a clinical study titled "A Study of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Cancer Patients Undergoing Chemotherapy". The goal of this clinical trial is to assess whether Shengbai Oral Formula is a viable option for treatment of fatigue, pain, and neutropenia in patients undergoing their third cycle of chemotherapy.

What is the current status of trial NCT06706752?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-01-24. Estimated completion is 2025-12.

What conditions does trial NCT06706752 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT06706752?

The interventions under investigation include: Shengbai Oral Formula (DIETARY_SUPPLEMENT), Inactive Placebo (OTHER).

Who is sponsoring clinical trial NCT06706752?

This trial is sponsored by Sutter Health, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06706752 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.